Streetbeat News

Products Services

BGNE

On March 13, 2024, the FDA approved Beigene's Tevimbra, marking a significant milestone for the company in the pharmaceutical industry. This approval could potentially enhance Beigene's market position and financial performance.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 6:13 pm

ACB

CGC

TLRY

VFF

Village Farms International, Inc. (NASDAQ:VFF) has secured the #2 spot in Canada's recreational cannabis market, showing significant financial improvement and market share growth. The company's effective cost management and low production costs have contributed to its success, alongside a notable increase in exports. VFF's cannabis division reports an 11% sequential increase in net sales, with a strong emphasis on branded sales. The U.S. CBD business has also seen a significant increase in EBITDA despite a sales dip. Analyst Pablo Zuanic highlights VFF's potential for continued market share gains and improved gross margins.

Portfolio Pulse from Nicolás Jose Rodriguez

March 14, 2024 | 6:12 pm

IFNNY

NVDA

TSLA

WKSP

Tesla Inc (NASDAQ:TSLA) faces a cooling EV market, impacting its growth projections. Worksport (NASDAQ:WKSP) is innovating in the automotive industry with its solar-powered products and partnership with Infineon Technologies AG (OTC:IFNNY) to use GaN semiconductors, aiming to surpass the current silicon-based solutions like those from NVIDIA Corporation (NASDAQ:NVDA). Nvidia is also exploring new technologies beyond silicon, as indicated by its upcoming GTC AI Conference.

Portfolio Pulse from Upwallstreet

March 14, 2024 | 6:06 pm

ETH-USD

On Wednesday, 12,325.35 Ether (ETH) worth approximately $47.7 million was burned, permanently removing it from circulation. This action follows the Ethereum blockchain's EIP-1159 upgrade, which introduced a variable base fee for transactions that is burned, contributing to a decrease in Ether's supply. The current issuance rate of new Ether is 4% annually, expected to drop to 0.5-1% with the Ethereum 2.0 upgrade, potentially making ETH a deflationary currency. The net annualized issuance rate for Ether was -15.35% yesterday.

Portfolio Pulse from Benzinga Insights

March 14, 2024 | 6:00 pm

MARA

RIOT

Marathon Digital Holdings, Inc. (MARA) and Riot Platforms, Inc. (RIOT) shares are trading lower due to continued downward momentum and a pullback in Bitcoin. Both companies have seen their shares decline over 35% in the last 30 days, attributed to disappointing Bitcoin production numbers, worse-than-expected earnings, and anticipation of the Bitcoin halving event in April. MARA has an average 1-year price target of $29.20, indicating a potential upside of 60.53%, with bullish ratings from analysts.

Portfolio Pulse from Erica Kollmann

March 14, 2024 | 5:47 pm

GEHC

GE HealthCare (GEHC) and Hartford HealthCare have renewed their Care Alliance agreement for another 7 years, aiming to enhance patient care and access in Connecticut. The collaboration will focus on innovation, improving patient and staff experiences, and advancing imaging technologies through 2030.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 5:31 pm

SIDU

Sidus Space, Inc. (NASDAQ:SIDU) shares dropped 1.1% to $3.570 after announcing the successful launch and deployment of its LizzieSat satellite via SpaceX's Transporter-10 Rideshare mission. The company confirmed receiving signals from LizzieSat in low Earth orbit and plans to launch two more satellites later this year for intelligence solutions in various industries.

Portfolio Pulse from Nabaparna Bhattacharya

March 14, 2024 | 5:09 pm

IOVA

Piper Sandler has reaffirmed its Overweight rating on Iovance Biotherapeutics (NASDAQ:IOVA), increasing its price target from $18.00 to $19.00. The adjustment reflects a potential 28.81% upside from the current share price of $14.75. Iovance Biotherapeutics, a clinical-stage biopharmaceutical company, is focused on developing personalized T-cell therapies for solid tumor cancers and is preparing for potential U.S. regulatory approvals and commercialization.

Portfolio Pulse from Benzinga Insights

March 14, 2024 | 5:00 pm

JAZZ

HC Wainwright & Co. has maintained its Buy rating for Jazz Pharmaceuticals (NASDAQ:JAZZ) but lowered its price target from $204 to $200. Despite this, shares of Jazz Pharmaceuticals have seen a slight increase of 0.2% in the last 24 hours, trading at $118 per share. A move to the new price target would represent a 69.49% increase from the current share price. Jazz Pharmaceuticals, an Ireland-based biopharmaceutical company, focuses on treatments for sleeping disorders and oncology, with nine approved drugs in its portfolio.

Portfolio Pulse from Benzinga Insights

March 14, 2024 | 5:00 pm

IMRX

Immuneering's shares dropped following the announcement of topline results from the Phase 1 portion of its Phase 1/2a clinical trial of IMM-1-104 in advanced RAS-mutant solid tumors.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 4:52 pm